Abstract

The functions of G-protein-coupled receptors (GPCRs) are primarily mediated and modulated by three families of proteins: the heterotrimeric G proteins, the G-protein-coupled receptor kinases (GRKs) and the arrestins1. G proteins mediate activation of second-messenger-generating enzymes and other effectors, GRKs phosphorylate activated receptors2, and arrestins subsequently bind phosphorylated receptors and cause receptor desensitization3. Arrestins activated by interaction with phosphorylated receptors can also mediate G-protein-independent signalling by serving as adaptors to link receptors to numerous signalling pathways4. Despite their central role in regulation and signalling of GPCRs, a structural understanding of β-arrestin activation and interaction with GPCRs is still lacking. Here we report the crystal structure of β-arrestin-1 (also called arrestin-2) in complex with a fully phosphorylated 29-amino-acid carboxy-terminal peptide derived from the human V2 vasopressin receptor (V2Rpp). This peptide has previously been shown to functionally and conformationally activate β-arrestin-1 (ref. 5). To capture this active conformation, we used a conformationally selective synthetic antibody fragment (Fab30) that recognizes the phosphopeptide-activated state of β-arrestin-1. The structure of the β-arrestin-1–V2Rpp–Fab30 complex shows marked conformational differences in β-arrestin-1 compared to its inactive conformation. These include rotation of the amino- and carboxy-terminal domains relative to each other, and a major reorientation of the ‘lariat loop’ implicated in maintaining the inactive state of β-arrestin-1. These results reveal, at high resolution, a receptor-interacting interface on β-arrestin, and they indicate a potentially general molecular mechanism for activation of these multifunctional signalling and regulatory proteins.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Protein Data Bank

Data deposits

Coordinates and structure factors for the b-arrestin-1–V2Rpp– Fab30 complex are deposited in the Protein Data Bank under accession code 4JQI.

References

  1. 1.

    , & Seven-transmembrane receptors. Nature Rev. Mol. Cell Biol. 3, 639–650 (2002)

  2. 2.

    & G proteins. Trends Biochem. Sci. 17, 383–387 (1992)

  3. 3.

    & Desensitization of G protein-coupled receptors. Recent Prog. Horm. Res. 51, 319–351; discussion. 352–313 (1996)

  4. 4.

    & Transduction of receptor signals by β-arrestins. Science 308, 512–517 (2005)

  5. 5.

    , , , & The active conformation of β-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of β-arrestins1 and -2. J. Biol. Chem. 282, 21370–21381 (2007)

  6. 6.

    & The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 110, 465–502 (2006)

  7. 7.

    , , & Activation-dependent conformational changes in β-arrestin 2. J. Biol. Chem. 279, 55744–55753 (2004)

  8. 8.

    et al. Involvement of distinct arrestin-1 elements in binding to different functional forms of rhodopsin. Proc. Natl Acad. Sci. USA 110, 942–947 (2013)

  9. 9.

    et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450, 383–387 (2007)

  10. 10.

    et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011)

  11. 11.

    et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J. Mol. Biol. 373, 924–940 (2007)

  12. 12.

    , , , & Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem. 274, 32248–32257 (1999)

  13. 13.

    , & A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255, 7108–7117 (1980)

  14. 14.

    , , , & Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J. Biol. Chem. 272, 28849–28852 (1997)

  15. 15.

    , , , & Crystal structure of β-arrestin at 1.9 Å: possible mechanism of receptor binding and membrane translocation. Structure 9, 869–880 (2001)

  16. 16.

    et al. Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. Proc. Natl Acad. Sci. USA 103, 4900–4905 (2006)

  17. 17.

    et al. An additional phosphate-binding element in arrestin molecule. Implications for the mechanism of arrestin activation. J. Biol. Chem. 275, 41049–41057 (2000)

  18. 18.

    et al. How does arrestin respond to the phosphorylated state of rhodopsin? J. Biol. Chem. 274, 11451–11454 (1999)

  19. 19.

    , , , & Role of the carboxyl-terminal region of arrestin in binding to phosphorylated rhodopsin. J. Biol. Chem. 266, 15334–15339 (1991)

  20. 20.

    et al. β-arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor. Nature 383, 447–450 (1996)

  21. 21.

    , , , & Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells. J. Biol. Chem. 274, 6831–6834 (1999)

  22. 22.

    , , , & Transition of arrestin into the active receptor-binding state requires an extended interdomain hinge. J. Biol. Chem. 277, 43961–43967 (2002)

  23. 23.

    & The molecular acrobatics of arrestin activation. Trends Pharmacol. Sci. 25, 105–111 (2004)

  24. 24.

    et al. Functional specialization of β-arrestin interactions revealed by proteomic analysis. Proc. Natl Acad. Sci. USA 104, 12011–12016 (2007)

  25. 25.

    et al. Conformation of receptor-bound visual arrestin. Proc. Natl Acad. Sci. USA 109, 18407–18412 (2012)

  26. 26.

    , & Distinct loops in arrestin differentially regulate ligand binding within the GPCR opsin. Nature Commun. 3, 995 (2012)

  27. 27.

    et al. Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins. Nature Struct. Mol. Biol. 18, 437–442 (2011)

  28. 28.

    Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal. Biochem. 231, 269–271 (1995)

  29. 29.

    & Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr. A 276, 307–326 (1997)

  30. 30.

    et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007)

  31. 31.

    et al. Crystal structure of full-length KcsA in its closed conformation. Proc. Natl Acad. Sci. USA 106, 6644–6649 (2009)

  32. 32.

    , , , & Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry 41, 3321–3328 (2002)

  33. 33.

    & Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004)

  34. 34.

    , & A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallogr. D 61, 850–855 (2005)

  35. 35.

    et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010)

  36. 36.

    The PyMOL Molecular Graphics System v.1.3r1. (2010)

  37. 37.

    & Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577–2637 (1983)

  38. 38.

    , & Model-free methods of analyzing domain motions in proteins from simulation: a comparison of normal mode analysis and molecular dynamics simulation of lysozyme. Proteins 27 425–437 (1997)

Download references

Acknowledgements

We thank D. Capel for technical assistance and V. Ronk, D. Addison and Q. Lennon for administrative and secretarial support. We thank S. Ahn and L. Wingler for critical reading of the manuscript. We acknowledge support from the Stanford Medical Scientist Training Program and the American Heart Association (A.M.), from the National Science Foundation (A.C.K.), from the National Institutes of Health Grants NS028471 (B.K.K.), HL16037 and HL70631 (R.J.L.), GM072688 and GM087519 (A.A.K. and S.K.), HL 075443 (K.X.) and from the Mathers Foundation (B.K.K. and W.I.W.). R.I.R is supported by a post-doctoral fellowship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–CAPES. R.J.L. is an investigator with the Howard Hughes Medical Institute.

Author information

Author notes

    • Arun K. Shukla
    • , Aashish Manglik
    •  & Andrew C. Kruse

    These authors contributed equally to this work.

Affiliations

  1. Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA

    • Arun K. Shukla
    • , Kunhong Xiao
    • , Rosana I. Reis
    • , Wei-Chou Tseng
    • , Dean P. Staus
    • , Li-Yin Huang
    • , Prachi Tripathi-Shukla
    •  & Robert J. Lefkowitz
  2. Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305, USA

    • Aashish Manglik
    • , Andrew C. Kruse
    • , Daniel Hilger
    • , William I. Weis
    •  & Brian K. Kobilka
  3. Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois 60637, USA

    • Serdar Uysal
    • , Marcin Paduch
    • , Akiko Koide
    • , Shohei Koide
    •  & Anthony A. Kossiakoff
  4. Department of Structural Biology, Stanford University School of Medicine, Stanford, California 94305, USA

    • William I. Weis
  5. Howard Hughes Medical Institute. Duke University Medical Center, Durham, North Carolina 27710, USA

    • Robert J. Lefkowitz
  6. Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA

    • Robert J. Lefkowitz

Authors

  1. Search for Arun K. Shukla in:

  2. Search for Aashish Manglik in:

  3. Search for Andrew C. Kruse in:

  4. Search for Kunhong Xiao in:

  5. Search for Rosana I. Reis in:

  6. Search for Wei-Chou Tseng in:

  7. Search for Dean P. Staus in:

  8. Search for Daniel Hilger in:

  9. Search for Serdar Uysal in:

  10. Search for Li-Yin Huang in:

  11. Search for Marcin Paduch in:

  12. Search for Prachi Tripathi-Shukla in:

  13. Search for Akiko Koide in:

  14. Search for Shohei Koide in:

  15. Search for William I. Weis in:

  16. Search for Anthony A. Kossiakoff in:

  17. Search for Brian K. Kobilka in:

  18. Search for Robert J. Lefkowitz in:

Contributions

A.K.S. conceived the project, designed the Fab selection strategy, selected and characterized Fab30, established and optimized complex formation and purification conditions, prepared protein for crystallization trials and supervised the experiments related to the biochemical characterization of the complex. A.M. purified the complex, performed crystallography trials and grew crystals. A.M. and A.C.K. collected and processed diffraction data, and solved and refined the structure with supervision from W.I.W. R.I.R. assisted with advanced Fab characterization and optimized complex formation. W.-C.T. assisted with Fab selection and preliminary characterization. K.X. performed and analysed the crosslinking experiments. D.P.S. performed and analysed radioligand binding experiments. L.-Y.H. assisted with functional characterization of the complex. P.T.-S. expressed and purified the receptor. S.U., M.P., A.K., S.K. and A.A.K. generated and provided the phage display library and the screening protocol and helped with the initial phase of Fab selection. D.H. performed the comparison of the structural model with EPR data. A.K.S., A.M. and A.C.K. made figures. A.K.S., A.M., A.C.K., B.K.K. and R.J.L. wrote the manuscript. B.K.K. and R.J.L. supervised the overall research.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Brian K. Kobilka or Robert J. Lefkowitz.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Figures 1-7, Supplementary Methods, Supplementary Table 1 and Supplementary References.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature12120

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.